Top Line: Laryngeal cancer is one of the few early-stage cancers that still typically receives definitive radiation to the whole organ.
The Study: Much like prostate cancer, this was born both from concern of underappreciating the extent of disease on available imaging as well as from understanding the limits of our ability to accurately deliver conformal treatment to a target with internal motion. An important distinction from prostate cancer, which pathologically often involves the whole organ, is that early laryngeal cancer can often be cured with very targeted surgery removing only the affected cord. Even with the advent of IMRT and daily CBCT, these strategies have been incorporated more to minimize planning target volume (PTV) margin of error to avoid undue dose to carotid arteries than to minimize the clinical target volume (CTV) to anything less than the whole larynx and paraglottic tissue. After finessing a novel targeted approach through phase 1 study, the phase 2 LT-SABR trial explored 5-fraction radiation to a highly conformal laryngeal target. How?! CT simulations included 4D-scans with 1-mm slice thickness. This was used to delineate the gross tumor throughout the breathing cycle (iGTV) and, remarkably, there was no CTV but rather a direct 3-mm radial / 5-mm craniocaudal PTV margin. This allowed for optimization of dose not only to bilateral carotid arteries but also to bilateral arytenoids, thyroid and cricoid cartilage, and inferior constrictor muscles. The prescription was 42.5 Gy in 5 fractions delivered twice weekly when PTV was <10 cc (n=21) or 58.08 Gy in 16 fractions delivered daily when targets were larger or in the setting of active smoking (n=4). Note: their earlier phase 1 study in addition to prior investigations indicated increased risk for soft tissue necrosis when ablative radiation doses were delivered to active smokers. At a median follow-up of nearly 4 years, there have been two local recurrences (8%). What’s more, patient reported voice outcomes—the primary goal with these incrementally smaller fields—were excellent.
TBL: The LT-SABR regimen will be compared to whole larynx IMRT at 2.25 Gy per fraction in a follow-on randomized phase 2 trial. | Sher, Int J Radiat Oncol Biol Phy 2024
The Study: Much like prostate cancer, this was born both from concern of underappreciating the extent of disease on available imaging as well as from understanding the limits of our ability to accurately deliver conformal treatment to a target with internal motion. An important distinction from prostate cancer, which pathologically often involves the whole organ, is that early laryngeal cancer can often be cured with very targeted surgery removing only the affected cord. Even with the advent of IMRT and daily CBCT, these strategies have been incorporated more to minimize planning target volume (PTV) margin of error to avoid undue dose to carotid arteries than to minimize the clinical target volume (CTV) to anything less than the whole larynx and paraglottic tissue. After finessing a novel targeted approach through phase 1 study, the phase 2 LT-SABR trial explored 5-fraction radiation to a highly conformal laryngeal target. How?! CT simulations included 4D-scans with 1-mm slice thickness. This was used to delineate the gross tumor throughout the breathing cycle (iGTV) and, remarkably, there was no CTV but rather a direct 3-mm radial / 5-mm craniocaudal PTV margin. This allowed for optimization of dose not only to bilateral carotid arteries but also to bilateral arytenoids, thyroid and cricoid cartilage, and inferior constrictor muscles. The prescription was 42.5 Gy in 5 fractions delivered twice weekly when PTV was <10 cc (n=21) or 58.08 Gy in 16 fractions delivered daily when targets were larger or in the setting of active smoking (n=4). Note: their earlier phase 1 study in addition to prior investigations indicated increased risk for soft tissue necrosis when ablative radiation doses were delivered to active smokers. At a median follow-up of nearly 4 years, there have been two local recurrences (8%). What’s more, patient reported voice outcomes—the primary goal with these incrementally smaller fields—were excellent.
TBL: The LT-SABR regimen will be compared to whole larynx IMRT at 2.25 Gy per fraction in a follow-on randomized phase 2 trial. | Sher, Int J Radiat Oncol Biol Phy 2024

